Skip to main content

Table 2 Observed irAEs in patients who developed CPI related nephrotoxcity and their outcome

From: Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

Patient # CPI AKI severity Assosciated irAE Relation to AKI diagnosis Renal and non renal irAE outcome
11 Nivolumab Nephrotic syndrome Hypothyrodisim (G2) 4 weeks prior to AKI Persistent hypothyrodisim
Complete remission of nephrotic syndrome
14 Pembrolizumab G3 Colitis (G3) 2 weeks prior to AKI Diarrhea and renal function improved partially then patient developed 2nd AKI
2 Nivolumab G3 Elevated dsDNA and RNP titers At the time of AKI diagnosis Titers became undetectable after 4 week
Partial renal recovery
6 Nivolumab G3 Hypothyrodisim (G2) 10 weeks prior to AKI Persistent hypothyrodisim
Complete renal recovery
3 Nivolumab G3 Myositis 6 weeks after AKI Myosisits had resolved
Partial renal recovery
7 Tremelimumab G3 Dermatitis (G1)
Pneumonitis (G2)
At the time of AKI diagnosis Dermatitis and pneumonitis had resolved within 2 week
Partial renal recovery
15 Nivolumab G1 Hypothyrodisim (G2)
Esophagitis (G2)
5 weeks prior to AKI Esophagitis and AKI had fully recovered
Persistent hypothyrodisim
10 Pembrolizumab G3 Dermatitis (G1)
Pneumonitis (G2)
At the time of AKI diagnosis Dermatitis and pneumonitis had resolved within 1 week
Partial renal recovery
8 Nivolumab and Ipilimumab G3 Dermatitis (G1)
Thyroditis (G3)
Adrenal insuffiency (G1)
5 weeks prior to AKI Persistent hypothyrodisim and adrenal insuffiency
Complete renal recovery
  1. Common Terminology Criteria for Adverse Events (CTCAE)
  2. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
  3. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting ageappropriate instrumental ADL
  4. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL
  5. Grade 4 Life-threatening consequences; urgent intervention indicated
  6. CPI immue Checkpoint inhibitor, AKI acute kidney injury, irAE immue related adverse events